Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) EPS (Basic) (2020 - 2025)

Insight Molecular Diagnostics' EPS (Basic) history spans 6 years, with the latest figure at -$0.34 for Q3 2025.

  • For Q3 2025, EPS (Basic) rose 65.31% year-over-year to -$0.34; the TTM value through Sep 2025 reached -$1.89, up 62.43%, while the annual FY2024 figure was -$4.67, 24.53% down from the prior year.
  • EPS (Basic) for Q3 2025 was -$0.34 at Insight Molecular Diagnostics, down from -$0.31 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.4 in Q1 2023 and bottomed at -$8.03 in Q4 2022.
  • The 5-year median for EPS (Basic) is -$0.36 (2024), against an average of -$1.04.
  • The largest annual shift saw EPS (Basic) plummeted 1907.5% in 2022 before it skyrocketed 463.64% in 2023.
  • A 5-year view of EPS (Basic) shows it stood at -$0.4 in 2021, then tumbled by 1907.5% to -$8.03 in 2022, then soared by 68.12% to -$2.56 in 2023, then fell by 0.49% to -$2.57 in 2024, then skyrocketed by 86.78% to -$0.34 in 2025.
  • Per Business Quant, the three most recent readings for IMDX's EPS (Basic) are -$0.34 (Q3 2025), -$0.31 (Q2 2025), and -$0.26 (Q1 2025).